Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy

Arthritis and Rheumatism

Volumn 39, Issue 6, 1996, Pages 996-1005

  Möttönen, Timo ^a   Paimela, Leena ^b   Ahonen, Jari ^c   Helve, Tapani ^b   Hannonen, Pekka ^c   Leirisalo Repo, Marjatta ^d  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b Malmi Hospital   (Finland)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; GOLD; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0029941459     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390617     Document Type: Article

References (56)

1. Cash JM, Klippel JH: Second-line drug therapy for rheumatoid arthritis. N Engl J Med 19:1368-1375, 1994
2. Lipsky PE: Remission-inducing therapy in rheumatoid arthritis. Am J Med 31:40-49, 1983
3. Kushner I: Does aggressive therapy of rheumatoid arthritis affect outcome? J Rheumatol 16:1-4, 1989
4. Van der Heijde DMFM, van Riel PL, Nuver-Zwart IH, van de Putte LBA: Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-years follow-up (letter). Lancet 335:539, 1990
5. Borg G, Allander E, Berg E, Brodin U, Trang L: Auranofin treatment in early rheumatoid arthritis may postpone early retirement: results from a 2-year double blind trial. J Rheumatol 18:1015-1020, 1991
6. Hannonen P, Möttönen T, Hakola M, Oka M: Sulfasalazine in early rheumatoid arthritis: a 48-week, double-blind, prospective, placebo-controlled study. Arthritis Rheum 36:1501-1509, 1993
7. Luukkainen R, Kajander A, Isomäki H: Effect of gold on progression of erosions in rheumatoid arthritis: better results with early treatment. Scand J Rheumatol 6:189-192, 1977
8. Wolfe F: 50 years of antirheumatic therapy: the prognosis of rheumatoid arthritis. J Rheumatol 17:24-32, 1990
9. Iannuzzi L, Dawson N, Zein N, Kushner I: Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med 309:1023-1028, 1983
10. Kirwan JR, Currey HLF: Rheumatoid arthritis: disease-modifying antirheumatic drugs. Clin Rheum Dis 9:581-599, 1983
11. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF: The development of disability in rheumatoid arthritis. Arthritis Rheum 29:494-500, 1986
12. Scott DL, Spector TD, Pullar T, McConkey B: What should we hope to achieve when treating rheumatoid arthritis? Ann Rheum Dis 48:256-261, 1989
13. Pincus T: Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 41:1037-1041, 1988
14. Wolfe F, Hawley DJ, Cathey MA: Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 17:994-1002, 1990
15. Situnayake RD, Grindulis KA, McConkey B: Long term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis 46:177-183, 1987
16. Thompson PW, Kirwan JR, Barnes CG: Practical results of treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol 24:167-175, 1985
17. Fries JF: Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol 17:12-15, 1990
18. Wilske KR, Healey LA: Remodeling the pyramid: a concept whose time has come. J Rheumatol 16:565-567, 1989
19. Bensen WG, Bensen W, Adachi JD, Tugwell PX: Remodelling the pyramid: the therapeutic target of rheumatoid arthritis. J Rheumatol 17:987-989, 1990
20. Hess EV, Luggen ME: Remodelling the pyramid: a concept whose time has not yet come. J Rheumatol 16:1175-1176, 1989
21. Pincus T, Callahan LF: Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis: lessons from Hodgkin's disease and coronary artery disease. J Rheumatol 17:1582-1585, 1990
22. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA: 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 9:175-176, 1958
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988
24. Möttönen TT: Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 47:648-653, 1988
25. Paimela L, Leirisalo-Repo M, Helve T, Koskimies S: The prognostic value of HLA DR4 and B27 antigens in early rheumatoid arthritis. Scand J Rheumatol 22:220-224, 1993
26. Mallya RK, Mace BEW: The assessment of disease activity in rheumatoid arthritis using a multivariate analysis. Rheumatol Rehabil 20:14-17, 1981
27. Ritchie DM, Doyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW: Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. QJM 37:393-406, 1968
28. Pinals RS, Masi AT, Larsen RA, The Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24:1308-1315, 1981
29. Larsen A, Dale K, Eek M: Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 18:481-491, 1977
30. Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA 140:659-662, 1949
31. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP: Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 26:1346-1353, 1983
32. Jacoby RK, Jayson MIV, Cosh JA: Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. BMJ 2:96-100, 1973
33. Eberhardt KB, Rydgren LC, Petterson H, Wollheim FA: Early rheumatoid arthritis: onset, course, and outcome over 2 years. Rheumatol Int 10:135-142, 1990
34. Eberhardt K, Grubb R, Johnson U, Pettersson H: HLA-DR antigens, GM allotypes and antiallotypes in early rheumatoid arthritis: their relation to disease progression. J Rheumatol 20: 1825-1829, 1993
35. Eberhardt K, Truedsson L, Pettersson H, Svensson B, Stigsson L, Eberhardt JL, Wollheim FA: Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA, and IgM rheumatoid factor. Ann Rheum Dis 49:906-909, 1990
36. Eberhardt K, Fex E, Johnsson K, Geborek P: Hip involvement in early rheumatoid arthritis. Ann Rheum Dis 54:45-48, 1995
37. Van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, Koster AM, van't Hof MA, van Rijswijk MH, van de Putte LBA: Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 35:26-34, 1992
38. Van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LBA: Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 31:519-525, 1992
39. Rasker JJ, Cosh JA: Long-term effects of treating rheumatoid arthritis. Baillieres Clin Rheumatol 6:141-160, 1992
40. Van der Heijde DMFM, van Riel PLCM, van Rijswijk MH, van de Putte LBA: Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum 17:284-292, 1988
41. Scott DL, Huskisson EC: The course of rheumatoid arthritis. Baillieres Clin Rheumatol 6:1-21, 1992
42. Van der Linden SM, Tugwell P: Pitfalls in assessment of prognosis. J Rheumatol 15:725-727, 1988
43. Hochberg MC: Predicting the prognosis of patients with rheumatoid arthritis: is there a crystal ball? J Rheumatol 20:1265-1267, 1993
44. Pincus T, Callahan LF: How many types of patients meet classification criteria for rheumatoid arthritis? J Rheumatol 21:1385-1389, 1994
45. Spector TD, Scott DL: What happens to patients with rheumatoid arthritis? The long-term outcome of treatment. Clin Rheumatol 7:315-330, 1988
46. Van Zeben D, Hazes JMW, Zwinderman AH, Vandenbroucke JP, Breedveld FC: The severity of rheumatoid arthritis: a 6-year followup study of younger women with symptoms of recent onset. J Rheumatol 21:1620-1625, 1994
47. Hakala M, Nieminen P, Koivisto O: More evidence from a community based series of better outcome in rheumatoid arthritis: data on the effect of multidisciplinary care on the retention of functional ability. J Rheumatol 21:1432-1437, 1994
48. Furst DE: Rational use of disease-modifying antirheumatic drugs. Drugs 39:19-37, 1990
49. Wolfe F, Hawley DJ: Remission in rheumatoid arthritis. J Rheumatol 12:245-252, 1985
50. Donnelly S, Scott DL, Emery P: The long-term outcome and justification for early treatment. Baillieres Clin Rheumatol 6:251-283, 1992
51. Scott DL, Coulton BL, Symmons DPM, Popert AJ: The long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1:1108-1111, 1987
52. Brook A, Corbett M: Relationship of radiological change to clinical outcome in rheumatoid arthritis. Ann Rheum Dis 36:274-275, 1977
53. Kaarela K, Sarna S: Correlation between clinical facets of outcome in rheumatoid arthritis. Clin Exp Rheumatol 11:643-644, 1993
54. Kaarela K: Prognostic factors and diagnostic criteria in early rheumatoid arthritis. Scand J Rheumatol [Suppl 57] 14:1-54, 1985
55. Sharp JT, Lidsky MD, Duffy J: Clinical responses during gold therapy for rheumatoid arthritis: changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities. Arthritis Rheum 25:540-549, 1982
56. Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, Decker JL, Genant HK, Gofton JP, Goodman N, Larsen A, Lidsky MD, Pussila P, Weinstein AS, Weissman BN: How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 28:1326-1335, 1985